Dermorphin
Dermorphin Acetate · DRM
Dermorphin is a heptapeptide (Tyr-D-Ala-Phe-Gly-Tyr-Pro-Ser) originally isolated from the skin of South American Phyllomedusa frogs. It is a highly selective mu-opioid receptor agonist with 30-40 times the analgesic potency of morphine on a per-molecule basis. Notably contains a D-alanine residue at position 2 - the first naturally-occurring D-amino-acid-containing peptide identified - which confers metabolic stability against enzymatic degradation.
Starting dose. N/A - extreme overdose risk
Strongly discouraged for non-research use. Naloxone availability mandatory for any opioid handling. Cross-tolerance with all other opioids.
Start here. Every protocol below is ordered lowest-first. Begin at the smallest effective dose, hold about a week to assess tolerance, and step up only if needed.
How it works
Dermorphin binds mu-opioid receptors (μ-OR / OPRM1) with high selectivity and 30-40x greater potency than morphine on a per-molecule basis. Mu-OR activation triggers Gi/Go signaling, inhibiting adenylyl cyclase, reducing cAMP, and activating G-protein-coupled inwardly rectifying potassium (GIRK) channels - net producing neuronal hyperpolarization and decreased neurotransmitter release.
Analgesia
Spinal and supraspinal mu-OR activation produces potent analgesia, particularly for visceral and somatic pain.
D-Alanine Stability
The D-amino acid at position 2 resists enzymatic degradation - dermorphin survives proteolysis better than mammalian opioid peptides like enkephalins, giving it a longer functional duration.
Reward / Reinforcement
Mu-OR activation in the ventral tegmental area and nucleus accumbens drives the reward circuitry - basis of euphoria and addictive potential. Standard opioid abuse pharmacology applies.
Respiratory Depression
Mu-OR in the brainstem respiratory centers - dose-dependent respiratory depression is the dominant overdose risk. Naloxone reverses dermorphin overdose effectively (mu-OR is competitive antagonism target).
Cross-Tolerance
Cross-tolerant with other mu-opioid agonists (morphine, fentanyl, oxycodone, heroin). Withdrawal symptoms similar to other opioids.
Potency Caveat
30-40x morphine potency means small volume errors translate to large dose errors - high overdose risk in research-chemical handling.
What to expect
Acute analgesic and euphoric effect within 30-60 min of SubQ dosing.
Tolerance develops with repeated use; dose escalation typical.
Dependence syndrome; withdrawal upon cessation.
Evidence
Claims we could not support
No abstract we checked supports these for this molecule at this route. That is not the same as saying they are false — it marks where the evidence is missing.
Quick-start dose/route. The page gives no community dose and labels use not recommended; no PubMed abstract can validate N/A as an administered regimen.
Mechanism: native Dermorphin is a highly selective, 30-40x-morphine mu-opioid agonist with Gi/Go signaling. No checked native-Dermorphin human abstract stated this full mechanism and potency. DALDA, [Lys7]dermorphin, and other analogues were rejected as identity mismatches.
Primary safety: human respiratory depression, dependence, and overdose risk. No native-Dermorphin human abstract directly established this. Rat PMID 1675473 was not promoted to human safety. Embedded PMIDs 10977879 and 1318369 resolve to unrelated papers.
Side effects & safety
Commonly reported
- Sedation
- Respiratory depression
- Constipation
- Nausea
- Pruritus (opioid-class itch)
- Euphoria
Less common & notes
- Severe respiratory depression and overdose death - the dominant opioid mortality pathway.
- Tolerance, dependence, and withdrawal syndrome.
- Hyperalgesia with chronic use.
- Hypotension.
- Pulmonary edema (rare).
- Allergic reactions rare.
- The high potency vs morphine combined with research-chemical-grade variability in actual peptide content makes overdose risk substantial.
Pharmacokinetics
Plasma
SubQ
Analgesic effect
subQ ~80%
Per dose
Hepatic
Storage. Refrigerate. Lyophilized form more stable.
Regulatory status
Not FDA-approved for any human indication. Functionally a high-potency opioid - while sold as research chemical, regulatory enforcement against opioid distribution may apply depending on jurisdiction. WADA prohibited under class S6 (narcotics) and various racing authority bans. Strongly discouraged for non-research use.
Put it to work
Calculate, log & track
Open Dermorphin straight into OnePin with your vial and dose pre-filled, then let it handle the syringe math and remind you before the vial runs out.
Open Dermorphin in the app →Go deeper
The guide & community
The complete Dermorphin walkthrough, real protocol discussion and coaching live inside the BlessUp community on Skool.
Join the community ↗